Recent Updates on Cancer Immunotherapy

Overview

Journal Precis Clin Med

Publisher Oxford University Press

Specialty General Medicine

Date 2019 Jan 29

PMID 30687562

Citations 56

Authors

Ming Liu

Fukun Guo

Affiliations

Soon will be listed here.

Abstract

Traditional cancer therapies include surgery, radiation, and chemotherapy, all of which are typically non-specific approaches. Cancer immunotherapy is a type of cancer treatment that helps the immune system fight cancer. Cancer immunotherapy represents a standing example of precision medicine: immune checkpoint inhibitors precisely target the checkpoints; tumor infiltrating lymphocytes, TCR T cells, and CAR T cells precisely kill cancer cells through tumor antigen recognition; and cancer vaccines are made from patient-derived dendritic cells, tumor cell DNA, or RNA, or oncolytic viruses, thus offering a type of personalized medicine. This review will highlight up-to-date advancement in most, if not all, of the immunotherapy strategies.

Citing Articles

Knee Desmoplastic Melanoma, an Uncommon Tumor, Disguised as a Malignant Peripheral Nerve Sheath Tumor: A Case Report and Review of the Literature.

Bailal H, Jebrouni F, El Ouardani S, Al Jarroudi O, Brahmi S, Afqir S Cureus. 2025; 16(12):e76524.

PMID: 39872575 PMC: 11771772. DOI: 10.7759/cureus.76524.

Analysis of the association between immune-related adverse events and the effectiveness in patients with advanced non-small-cell-lung cancer.

Chen H, Xu Y, Liu J, Yang S, Jiang H, Chen Z Discov Oncol. 2024; 15(1):534.

PMID: 39379639 PMC: 11461362. DOI: 10.1007/s12672-024-01413-2.

India's Potential as a Leader in Cancer Care Progress in the Future: A Synthetic Interdisciplinary Perspective.

Singh A, Velu U, Lewis S, Nittala R, Yang J, Vijayakumar S Cureus. 2024; 16(10):e70892.

PMID: 39376975 PMC: 11457899. DOI: 10.7759/cureus.70892.

Development of Cell and Gene Therapies for Clinical Use in the US and EU: Summary of Regulatory Guidelines.

Rotte A Curr Gene Ther. 2024; 25(1):10-21.

PMID: 38676481 DOI: 10.2174/0115665232306205240419091414.

Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer.

Bailey M, Morand S, Royfman R, Lin L, Singh A, Stanbery L Int J Mol Sci. 2024; 25(6).

PMID: 38542143 PMC: 10970335. DOI: 10.3390/ijms25063173.

References

Tanyi J, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R . Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018; 10(436). DOI: 10.1126/scitranslmed.aao5931. View

Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria J, Zitvogel L, Marabelle A . Rationale for anti-OX40 cancer immunotherapy. Eur J Cancer. 2015; 52:50-66. DOI: 10.1016/j.ejca.2015.08.021. View

Zhang D, Armstrong A, Tam S, McCarthy S, Luo J, Gilliland G . Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization. MAbs. 2017; 9(7):1129-1142. PMC: 5627589. DOI: 10.1080/19420862.2017.1358838. View

Best S, de Souza D, Kersbergen A, Policheni A, Dayalan S, Tull D . Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment. Cell Metab. 2018; 27(4):935-943.e4. DOI: 10.1016/j.cmet.2018.02.006. View

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Litzinger M, Fernando R, Curiel T, Grosenbach D, Schlom J, Palena C . IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood. 2007; 110(9):3192-201. PMC: 2200901. DOI: 10.1182/blood-2007-06-094615. View

Sugiura A, Rathmell J . Metabolic Barriers to T Cell Function in Tumors. J Immunol. 2018; 200(2):400-407. PMC: 5777533. DOI: 10.4049/jimmunol.1701041. View

Rosenberg S . IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014; 192(12):5451-8. PMC: 6293462. DOI: 10.4049/jimmunol.1490019. View

Katlinski K, Gui J, Katlinskaya Y, Ortiz A, Chakraborty R, Bhattacharya S . Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. Cancer Cell. 2017; 31(2):194-207. PMC: 5313042. DOI: 10.1016/j.ccell.2017.01.004. View

10.

Chao J, Savage P . Unlocking the Complexities of Tumor-Associated Regulatory T Cells. J Immunol. 2018; 200(2):415-421. PMC: 5763514. DOI: 10.4049/jimmunol.1701188. View

11.

Kato Y, Ozawa S, Miyamoto C, Maehata Y, Suzuki A, Maeda T . Acidic extracellular microenvironment and cancer. Cancer Cell Int. 2013; 13(1):89. PMC: 3849184. DOI: 10.1186/1475-2867-13-89. View

12.

Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View

13.

Sahin U, Tureci O . Personalized vaccines for cancer immunotherapy. Science. 2018; 359(6382):1355-1360. DOI: 10.1126/science.aar7112. View

14.

Gros A, Parkhurst M, Tran E, Pasetto A, Robbins P, Ilyas S . Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016; 22(4):433-8. PMC: 7446107. DOI: 10.1038/nm.4051. View

15.

LaFleur M, Muroyama Y, Drake C, Sharpe A . Inhibitors of the PD-1 Pathway in Tumor Therapy. J Immunol. 2018; 200(2):375-383. PMC: 5924692. DOI: 10.4049/jimmunol.1701044. View

16.

Bersanelli M, Buti S, Camisa R, Brighenti M, Lazzarelli S, Mazza G . Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy. Cancers (Basel). 2014; 6(4):2035-48. PMC: 4276955. DOI: 10.3390/cancers6042035. View

17.

Vinay D, Ryan E, Pawelec G, Talib W, Stagg J, Elkord E . Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015; 35 Suppl:S185-S198. DOI: 10.1016/j.semcancer.2015.03.004. View

18.

Thommen D, Schumacher T . T Cell Dysfunction in Cancer. Cancer Cell. 2018; 33(4):547-562. PMC: 7116508. DOI: 10.1016/j.ccell.2018.03.012. View

19.

Topalian S, Taube J, Anders R, Pardoll D . Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016; 16(5):275-87. PMC: 5381938. DOI: 10.1038/nrc.2016.36. View

20.

Ostrand-Rosenberg S, Fenselau C . Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment. J Immunol. 2018; 200(2):422-431. PMC: 5765878. DOI: 10.4049/jimmunol.1701019. View